Revenue - Collaboration revenue for Q4 2024 was 1.8 million in Q4 2023, attributed to a prior strategic collaboration with Ono Pharmaceutical[3] - Full year 2024 collaboration revenue increased to 5.5 million in 2023, driven by the strategic collaboration with Ono Pharmaceutical[5] Research and Development Expenses - Research and development expenses decreased to 10.9 million in Q4 2023, primarily due to reduced drug substance manufacturing and clinical trial costs[4] - Full year 2024 research and development expenses were 40.8 million in 2023, mainly due to lower clinical trial costs and employee compensation[6] General and Administrative Expenses - General and administrative expenses for Q4 2024 were 4.6 million in Q4 2023, primarily due to reduced professional fees[4] Financial Position - As of December 31, 2024, the company had 48.5 million in 2023[7] Strategic Developments - The company successfully regained worldwide development and commercialization rights for CUE-401, its lead autoimmune program[2] - The company advanced research on CUE-501, demonstrating potential to harness anti-viral specific T cells against pathogenic cells[2] - The management team was strengthened with the appointment of key industry leaders, enhancing strategic capabilities[2] - The company plans to announce a business update call and webcast in the coming weeks[2]
Cue Biopharma(CUE) - 2024 Q4 - Annual Results